v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenues:    
Total revenues $ 58,587 $ 59,551
Cost of revenues:    
Total cost of revenues 29,040 28,427
Gross profit 29,547 31,124
Operating expenses:    
Research and development 43,824 45,844
Sales and marketing 11,603 10,367
General and administrative (includes related party expense of $165 and $109, respectively) 22,914 25,802
Total operating expenses 78,341 82,013
Loss from operations (48,794) (50,889)
Other (expense) income:    
Change in fair value of equity investments (13,487) (13,095)
Other income 2,663 4,204
Total other expense (10,824) (8,891)
Loss before income taxes (59,618) (59,780)
Income tax expense 408 28
Net loss $ (60,026) $ (59,808)
Net loss per share of common and limited common stockholders, basic (in USD per share) $ (0.81) $ (0.82)
Net loss per share of common and limited common stockholders, diluted (in USD per share) $ (0.81) $ (0.82)
Weighted average shares used to compute net loss per share of common and limited common stockholders, basic (in shares) 73,989,137 73,057,916
Weighted average shares used to compute net loss per share of common and limited common stockholders, diluted (in shares) 73,989,137 73,057,916
Software products and services    
Revenues:    
Total revenues $ 35,560 $ 44,972
Cost of revenues:    
Total cost of revenues 10,863 9,112
Drug discovery    
Revenues:    
Total revenues 22,879 10,236
Cost of revenues:    
Total cost of revenues 16,310 14,452
Contribution    
Revenues:    
Total revenues 148 4,343
Cost of revenues:    
Total cost of revenues $ 1,867 $ 4,863